Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF2 | Q12772 | 1/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | AR | P10275 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | PKM | P14618 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8051375 | 1.00 | SREBF2 (0.70) | SREBF2CYP19A1KDM4EKMT2AAR | |
| SCHEMBL1181195 | 0.93 | KDM4E (0.75) | SREBF2CYP19A1KDM4EKMT2AAR | |
| SCHEMBL11212983 | 0.91 | SREBF2 (0.82) | SREBF2CYP19A1KDM4EKMT2AAR | |
| SCHEMBL11215130 | 0.91 | SREBF2 (0.82) | SREBF2CYP19A1KDM4EKMT2AAR | |
| SCHEMBL11213828 | 0.91 | SREBF2 (0.82) | SREBF2CYP19A1KDM4EKMT2AAR | |
| SCHEMBL11464717 | 0.89 | SREBF2 (0.79) | SREBF2CYP19A1KDM4EKMT2AAR | |
| SCHEMBL2781370 | 0.89 | KDM4E (0.85) | SREBF2CYP19A1KDM4EKMT2AAR | |
| SCHEMBL17409318 | 0.87 | CYP19A1 (0.71) | SREBF2CYP19A1KDM4EKMT2AAR | |
| SCHEMBL4267715 | 0.85 | KDM4E (0.68) | SREBF2CYP19A1KDM4EKMT2AAR | |
| SCHEMBL1181077 | 0.85 | HSD17B1 (0.84) | SREBF2CYP19A1KDM4EKMT2AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270199-A1 | THIAZOLE DERIVATIVES AND METHODS OF USING THE SAME | ARKANSAS STATE UNIV JONESBORO (US) | 2025-08-28 | — | — | US | claimed |
| US-20250270199-A1 | THIAZOLE DERIVATIVES AND METHODS OF USING THE SAME | ARKANSAS STATE UNIV JONESBORO (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2023192595-A1 | THIAZOLE DERIVATIVES AND METHODS OF USING THE SAME | Arkansas State University - Jonesboro (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| US-6706743-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2004-03-16 | — | — | US | disclosed |
| CN-1469876-A | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists | �Ʒ� | 2004-01-21 | — | — | CN | disclosed |
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-10-30 | — | — | US | disclosed |
| EP-1326861-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6566377-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-05-20 | — | — | US | disclosed |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | DAY ROBERT F (US) | 2002-05-02 | — | — | US | disclosed |
| WO-2002032897-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | SREBF2 1434/4885CYP19A1 534/4885KDM4E 3213/4885 |
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | SREBF2 1734/4885CYP19A1 561/4885KDM4E 3070/4885 |
| US-20250270199-A1 | THIAZOLE DERIVATIVES AND METHODS OF USING THE SAME | TST, GOT2, TPMT | SREBF2 2545/4885CYP19A1 2098/4885KDM4E 4630/4885 |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | ADRB3, ADRA1A, ADRB1 | SREBF2 1970/4885CYP19A1 531/4885KDM4E 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.